Assisted Reproductive Technology Market Analysis, Size, Segment To 2022 by Grand View Research, Inc.

Assisted Reproductive Technology Market Analysis By Procedure(Zygote Intrafallopian Transfer, Intracytoplasmic Sperm Injection,In Vitro Fertilization, Gamete Intrafallopian Transfer), By Cycle(Frozen Donor, Frozen Non-donor, Fresh Donor, Fresh Non-donor,New Treatment Procedures), And Segment Forecasts To 2022The Global Assisted Reproductive Technology (ART) market is expected to be alucrative market due to increasing obesity, rising disposable incomes, growingnumber of infertility issues, government support for infertility procedures,increasing number of smokers, stress, and pollution. According to the InternationalCouncil on Information Dissemination, one in every six couples is suffering frominfertility issues. With the growing infertility issues, the ART industry has grown10% every year. Moreover, the WHO 2014 report states that out of every 1.9billion obese people, 600 million people are overweight.For More Information on "Assisted Reproductive Technology MarketResearch Reports" visit - http://www.grandviewresearch.com/industryanalysis/assisted-reproductive-technology-market

The ART market is segmented on the basis of procedures and ART cycles. In vitrofertilization dominated the procedure segment of the market owing to its highersuccess rates, favorable reimbursement policies, and technology updates. To avoidmultiple births caused due to multiple sperm injection, time-lapse imaging hasbeen introduced. With this technology, egg division can be monitored and fate ofthe embryo can be decided prior.Frozen donor dominates the ART market as compared to fresh donor. Withtechnological shifts, many companies have now started online ordering, a strategyto expand and cover more market shares.North America dominates the industry due to awareness in people towards variousreproductive technologies and government initiatives to undertake extensiveresearch. To address various fertility issues, the Centers for Disease Control andPrevention (CDC) developed National Action Plan.

In Europe, an expert group is appointed to address various demographic issues. Inaddition, acceptance of the three-parent IVF procedure is expected to boom theART industry in Europe.Rising disposable incomes due to gain in education, low fertility rate, and familyplanning technology are some of the drivers attributing to the market expansion.The Asia Pacific Initiative on Reproduction (ASPIRE) strives to improve thequality of patient care by assisting physicians and clinicians to guide patients withvarious available reproductive technologies.Cryolab Ltd., Origio, Parallabs, IrvineScientific, European Sperm Bank, CosmosBiomedical, and Microm UK Ltd. dominate the industry. EmbryoScope byParallabs was launched in May 2013. This time-lapse monitoring was used inNovember 2014 for research by the American Society of Reproductive Medicine,where they increased the implantation and pregnancy rates.

In September 2012, Integramed America Inc. was acquired by Sagard CapitalPartners LP. The acquisition aims to expand Sagard Capital Partners LP presencein new areas with the help of Integramed America Inc. Industry players arecontinuously trying to introduce new ways to provide improved patient care and atthe same time achieve more revenue share and leadership. Key player initiativesalong with government funding are expected to make the ART more lucrative.Request TOC of “Assisted Reproductive Technology Market ResearchReports" visit - http://www.grandviewresearch.com/industryanalysis/assisted-reproductive-technology-market/request-tocAbout Grand View ResearchGrand View Research, Inc. is a U.S. based market research and consultingcompany, registered in the State of California and headquartered in San Francisco.The company provides syndicated research reports, customized research reports,and consulting services. To help clients make informed business decisions, thecompany offers market intelligence studies ensuring relevant and fact-basedresearch across a range of industries including technology, chemicals, materials,healthcare and energy.Contact:Sherry JamesCorporate Sales Specialist, U.S.A.Grand View Research, Inc.United StatesPhone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.comWebsite: Grand View ResearchBlog Site: http://www.divog.org/